کد مقاله کد نشریه سال انتشار مقاله انگلیسی ترجمه فارسی نسخه تمام متن
2659750 1140308 2016 4 صفحه PDF سفارش دهید دانلود کنید
عنوان انگلیسی مقاله ISI
Mending the Broken Heart: A Neprilysin Inhibitor for Heart Failure
ترجمه فارسی عنوان
ترمیم قلب های شکسته: یک بازدارنده Neprilysin برای نارسایی قلبی
کلمات کلیدی
Entresto؛ نارسایی قلبی؛ مهار کننده neprilysin؛ کاهش نسبت خروجی؛ sacubitril / والزارتان
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی پزشکی و دندانپزشکی (عمومی)
چکیده انگلیسی


• Sacubitril/valsartan was recently FDA approved to reduce morbidity and mortality in patients with reduced ejection fraction heart failure
• This medication is the first in the class of neprilysin inhibitors
• Sacubitril/valsartan could replace angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) as the standard of care in heart failure

Sacubitril/valsartan, an angiotensin-receptor neprilysin inhibitor, was recently approved by the United States Food and Drug Administration for reduction of morbidity and mortality in patients with heart failure with reduced ejection fraction. Sacubitril is the first drug in the neprilysin inhibitor class that assists with volume regulation by inhibiting the breakdown of brain natriuretic peptide. When compared with an angiotensin-converting enzyme inhibitor, sacubitril/valsartan demonstrated reductions in rehospitalization and all-cause mortality. Sacubitril/valsartan could replace angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: The Journal for Nurse Practitioners - Volume 12, Issue 3, March 2016, Pages e111–e114
نویسندگان
, , , ,